Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
09 sept. 2021 16h05 HE
|
Lyra Therapeutics
Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first...
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
17 août 2021 07h35 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
09 août 2021 16h05 HE
|
Lyra Therapeutics
- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 - - Licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets - ...
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
26 juil. 2021 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
12 juil. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
30 juin 2021 07h00 HE
|
Lyra Therapeutics
-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA),...
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
10 sept. 2020 18h00 HE
|
Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
03 sept. 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h05 HE
|
Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...